Immorta Bio Stem Cells Treat Rheumatoid Arthritis in Preclinical Studies
Rewriting the playbook on rheumatoid arthritis—Immorta Bio’s breakthrough anti‑aging stem‑cell therapy shows dramatic promise in preclinical trials. Their personalized pMSCs (patient‑derived mesenchymal stem cells) not only outperformed conventional bone‑marrow and umbilical‑cord sources, but also demonstrated superior effectiveness at reducing RA symptoms in lab models—marking a major leap forward in regenerative medicine and chronic inflammatory disease […]
Immorta Bio Inc. Announces Breakthrough in Liver Failure Treatment with Stem Cell Technology
Immorta Bio Inc., a company focused on longevity and regenerative medicine, has announced a significant breakthrough in the treatment of liver failure. The company is developing personalized stem cell technologies that show great promise in combating various diseases of aging. Immorta Bio’s research pipeline includes Personalized Regenerative Cells (PRCs), Personalized Mesenchymal Stem Cells (pMSCs), and […]
Revolutionizing Aging: Venvalo Group Unveils Immorta Bio, Inc for Personalized Cell Therapy in Age-Related Disease Treatment
Venvalo Group, a venture value optimization firm, has recently announced the formation of Immorta Bio, Inc. This new regenerative medicine company is set to revolutionize the treatment of aging and diseases associated with aging by providing patient-specific therapeutic solutions. Pioneering Personalized Regenerative Medicine Immorta Bio, Inc. is spearheading the development of personalized stem cell technologies, […]